Menu
Innovation Observatory > Reports > Neurology and Neurosurgery

Results

Drugs

December 2017

Dabigatran Etexilate (Pradaxa) for Secondary Stroke Prevention in Patients with Embolic Stroke of Undetermined Source – First Line

Dabigatran etexilate is an oral drug that acts by preventing clots from forming and blocking blood vessels. It is already available for the treatment and prevention of stroke and other types of blood clots affecting blood vessels and organs in the body. By preventing clots from forming, it can prevent future embolic strokes.

Drugs

December 2017

Cannabidiol (Epidiolex®) for Tuberous Sclerosis Complex – add-on therapy

Cannabidiol is a medicine that is being developed for the treatment of TSC patients who experience inadequately-controlled seizures. It is being developed as an oral medicine to be added to existing treatment options for TSC (‘add-on therapy’).

Drugs

December 2017

Ponesimod for Relapsing-remitting Multiple Sclerosis

Ponesimod is a drug which works by blocking the signals which allow the body’s immune cells to travel to and damage the nerve cells. By preventing the immune cells from damaging the nerves, it is thought this drug will stop the damage which causes MS ‘relapses’. In clinical trials it has been shown that ponesimod …

Drugs

October 2017

Galcanezumab for the prophylaxis of episodic and chronic migraine

Galcanezumab is being developed as one of a class of specific anti-migraine preventative drugs. By stopping a very specific protein in the brain and nervous system, galcanezumab reduces migraine attacks. Additionally as it is given once-a-month as treatment, it avoids the need to take numerous pills per day. If marketed, galcanezumab may be more preferable …

Drugs

October 2017

Fremanezumab for chronic and episodic migraine

  Fremanezumab is a new medicine under development for preventative treatment of chronic and episodic migraine. It acts by targeting a very specific type of protein called the human calcitonin gene-related peptide (CGRP) which is a well-known to be involved in migraine. Therefore, if licensed it will offer a potential new treatment option for patients …

Drugs

September 2017

Triheptanoin (UX-007) for glucose transporter type 1 deficiency syndrome (de vivo disease) – first line

Glucose transporter type 1 deficiency syndrome (Glut1 DS) is a rare genetic disorder that affects how the body moves glucose (used for energy) into the brain. The most common symptom of this condition is seizures (epilepsy), which usually begin within the first few months of life. However, the symptoms and severity of Glut1 deficiency syndrome …

Drugs

September 2017

Cethrin for traumatic spinal cord injury

A traumatic cervical spinal cord injury results from trauma (such as a fall or car crash, rather than from a disease), and affects the spinal cord in the upper part of the spine (known as the cervical spine). The spinal cord is the bundle of nerves that runs down the middle of the back, and …

Drugs

August 2017

Cloristridium botulinum Type A toxin (Dysport) for Spasmodic torticollis

Dystonia is a condition that causes muscle spasms and stiffening, which sometimes result in abnormal positions. Spasmodic torticollis is a form of dystonia affecting the neck specifically. The causes are not well understood, but in some cases it can be inherited, caused by other medicines, or as a result of another brain disease. Symptoms include …

Drugs

August 2017

SA-237 for neuromyelitis optica and neuromyelitis optica spectrum disorders

Neuromyelitis optica (Devic’s disease) is a rare autoimmune disorder (a condition where the immune system attacks itself). It is characterised by the inflammation of the nerve that leads from the eye to the brain, and the spinal cord. Symptoms consist of vision loss, loss of sensation, bladder dysfunction, weakness in limbs and paralysis and most …

Drugs

July 2017

Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years)

The current treatment is already licensed in adults, but is currently in a phase III trial for the treatment of multiple sclerosis in paediatric patients. Fingolimod will be administered orally once daily at a dose of either 0.5 mg or 0.25 mg depending on the patient’s body weight. If marketed this will become the first …

Get Alerts